Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elpipodect (MK-8189) in Healthy Volunteers and Schizophrenia Patients
NCT02181803Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2014
- Primary completion
- Apr 2015
01
Overview
Phase 1, randomised trial of elpipodect in schizophrenia and schizoaffective disorder (7 arms), sponsored by Merck & Co. Primary endpoints: Plasma Concentration at 24 Hours Post-dose, Area Under the Plasma-concentration Curve at Zero to 24 Hours Post-dose and 5 more. Started Aug 2014; status: completed.
02
Drugs
elpipodect
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on NCT02181803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02181803.